Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer

Celgene Corp. has committed more than $10bn to two big acquisitions already this year, but the company's biggest priority for its $12bn in cash as of the end of 2017 is to do more deals, executives said during a Jan. 25 fourth quarter earnings conference call.

The primary concern for Celgene's investors is how the company will replace revenue from its top-selling product Revlimid (lenalidomide) when the multiple myeloma blockbuster loses patent exclusivity around 2023. This month's acquisitions of Impact Biomedicines for $1.1bn up front and Juno Therapeutics Inc